Affymax, Inc.

The Barcelona-based, privately held mid-sized European pharmaceutical company, Grupo Ferrer Internacional SA , has sweetened its latest move to acquire cash-depleted Alexza Pharmaceuticals Inc.

All new intravenous and injectable drugs for patients with end-stage renal disease should be allowed two years of transitional payments from Medicare Part B before being lumped in with other drugs rei

Since taking control of Takeda Pharmaceutical Co. Ltd. ’s research and development in 2011, Tachi Yamada, MD, has wrought significant change on several fronts. Takeda’s chief medical and scientific

Syndax Pharmaceuticals Inc. ’s eight-year struggle as a biotech has reached a crescendo; the developer of epigenetic modifiers is ready to begin a late-stage pivotal trial of its lead drug candidate